Information Provided By:
Fly News Breaks for September 26, 2018
SGEN
Sep 26, 2018 | 06:39 EDT
JPMorgan analyst Cory Kasimov raised his price target for Seattle Genetics to $85 saying he's bullish on the potential success of ECHELON-2, which is expected to readout in Q4. The analyst, however, thinks expectations from investors are "relatively high." Nevertheless, another successful readout and material line extension for Adcetris could help maintain the stock's "impressive recent momentum," Kasimov tells investors in a research note. He keeps an Overweight rating on Seattle Genetics.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.